SpringerLink
Log in

Isavuconazole: Has It Saved Us? A Pharmacotherapy Review and Update on Clinical Experience

  • Fungal Infections (S Bernard, Section Editor)
  • Published:
Current Treatment Options in Infectious Diseases Aims and scope Submit manuscript

Opinion statement

The new triazole antifungal, isavuconazole, gained approval in 2015 for the treatment of invasive aspergillosis (IA) and mucormycosis in adult patients. Predictable pharmacokinetics, a favorable safety profile, and demonstrated clinical efficacy against a wide spectrum of yeasts and molds result in expansion of the antifungal armamentarium. The place in therapy for this medication has yet to be defined. This review aims to place isavuconazole’s role in therapy in perspective. Three studies evaluate isavuconazole activity in the treatment of IA, mucormycosis, and candidiasis. Isavuconazole was non-inferior to voriconazole in the treatment of IA and had similar outcomes to liposomal amphotericin (L-AMB) and posaconazole in the treatment of mucormycosis. Isavuconazole did not meet a priori non-inferiority margins for superior clinical outcome response in the treatment of candidemia. Cost-effectiveness analyses compare isavuconazole to other treatment options with favorable outcomes regarding isavuconazole use. Considering the potential for substantial cost savings, non-inferiority to L-AMB and other triazoles in terms of efficacy, a more favorable safety profile, and an oral formulation, isavuconazole has advantages over current standard of care for the treatment of IA and mucormycosis. For other invasive fungal infections including candidiasis, clinical outcome data and cost-effectiveness analysis are needed. Isavuconazole is a safe, effective, and fiscally responsible treatment option for the treatment of IA and mucormycosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (France)

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Wilson DT, Dimondi VP, Johnson SW, Jones TM, Drew RH. Role of isavuconazole in the treatment of invasive fungal infections. Ther Clin Risk Manag. 2016;12:1197–206.

    Article  PubMed  PubMed Central  Google Scholar 

  2. • Marty FM, Ostrosky-Zeichner L, Cornely OA, et al. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. Lancet Infect Dis. 2016;16(7):828–37. This is the seminal study examining the efficacy and safety of isavuconazole in the treatment of mucormycosis. This serves as the basis for package indication for the treatment of mucormycosis, which differentiates isavuconazole from other triazole antifungal agents

    Article  CAS  PubMed  Google Scholar 

  3. Thompson GR, Wiederhold NP. Isavuconazole: a comprehensive review of spectrum of activity of a new triazole. Mycopathologia. 2010;170(5):291–313.

    Article  CAS  PubMed  Google Scholar 

  4. Lepak AJ, Marchillo K, VanHecker J, Diekema D, Andes DR. Isavuconazole pharmacodynamic target determination for Candida species in an in vivo murine disseminated candidiasis model. Antimicrob Agents Chemother. 2013;57(11):5642–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Warn PA, Sharp A, Parmar A, Majithiya J, Denning DW, Hope WW. Pharmacokinetics and pharmacodynamics of a novel triazole, isavuconazole: mathematical modeling, importance of tissue concentrations, and impact of immune status on antifungal effect. Antimicrob Agents Chemother. 2009;53(8):3453–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Miceli MH, Kauffman CA. Isavuconazole: a new broad-spectrum triazole antifungal agent. Clin Infect Dis. 2015;61(10):1558–65.

    Article  CAS  PubMed  Google Scholar 

  7. Rybak JM, Marx KR, Nishimoto AT, Rogers PD. Isavuconazole: pharmacology, pharmacodynamics, and current clinical experience with a new triazole antifungal agent. Pharmacotherapy. 2015;35(11):1037–51.

    Article  CAS  PubMed  Google Scholar 

  8. Schmitt-Hoffmann A, Roos B, Heep M, et al. Single-ascending-dose pharmacokinetics and safety of the novel broad-spectrum antifungal triazole BAL4815 after intravenous infusions (50, 100, and 200 milligrams) and oral administrations (100, 200, and 400 milligrams) of its prodrug, BAL8557, in healthy volunteers. Antimicrob Agents Chemother. 2006;50(1):279–85.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Falci DR, Pasqualotto AC. Profile of isavuconazole and its potential in the treatment of severe invasive fungal infections. Infect Drug Resist. 2013;6:163–74.

    PubMed  PubMed Central  Google Scholar 

  10. Pettit NN, Carver PL. Isavuconazole: a new option for the management of invasive fungal infections. Ann Pharmacother. 2015;49(7):825–42.

    Article  CAS  PubMed  Google Scholar 

  11. Pfaller MA, Messer SA, Rhomberg PR, Jones RN, Castanheira M. In vitro activities of isavuconazole and comparator antifungal agents tested against a global collection of opportunistic yeasts and molds. J Clin Microbiol. 2013;51(8):2608–16.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Castanheira M, Messer SA, Rhomberg PR, Dietrich RR, Jones RN, Pfaller MA. Isavuconazole and nine comparator antifungal susceptibility profiles for common and uncommon Candida species collected in 2012: application of new CLSI clinical breakpoints and epidemiological cutoff values. Mycopathologia. 2014;178(1–2):1–9.

    Article  CAS  PubMed  Google Scholar 

  13. Guinea J, Pelaez T, Recio S, Torres-Narbona M, Bouza E. In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species. Antimicrob Agents Chemother. 2008;52(4):1396–400.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Seifert H, Aurbach U, Stefanik D, Cornely O. In vitro activities of isavuconazole and other antifungal agents against Candida bloodstream isolates. Antimicrob Agents Chemother. 2007;51(5):1818–21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Espinel-Ingroff A, Chowdhary A, Gonzalez GM, et al. Multicenter study of isavuconazole MIC distributions and epidemiological cutoff values for the Cryptococcus neoformans-Cryptococcus gattii species complex using the CLSI M27-A3 broth microdilution method. Antimicrob Agents Chemother. 2015;59(1):666–8.

    Article  CAS  PubMed  Google Scholar 

  16. Lepak AJ, Marchillo K, Vanhecker J, Andes DR. Isavuconazole (BAL4815) pharmacodynamic target determination in an in vivo murine model of invasive pulmonary aspergillosis against wild-type and cyp51 mutant isolates of Aspergillus fumigatus. Antimicrob Agents Chemother. 2013;57(12):6284–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Natesan SK, Chandrasekar PH. Isavuconazole for the treatment of invasive aspergillosis and mucormycosis: current evidence, safety, efficacy, and clinical recommendations. Infect Drug Resist. 2016;9:291–300.

    Article  PubMed  PubMed Central  Google Scholar 

  18. European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs. Available from: http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/AFST/Clinical_breakpoints/Antifungal_breakpoints_v_8.1_March_2017.pdf. March 1 2017. Accessed May 22 2017.

  19. Luo G, Gebremariam T, Lee H, Edwards JE Jr, Kovanda L, Ibrahim AS. Isavuconazole therapy protects immunosuppressed mice from mucormycosis. Antimicrob Agents Chemother. 2014;58(4):2450–3.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Yamazaki T, Inagaki Y, Fujii T, et al. In vitro activity of isavuconazole against 140 reference fungal strains and 165 clinically isolated yeasts from Japan. Int J Antimicrob Agents. 2010;36(4):324–31.

    Article  CAS  PubMed  Google Scholar 

  21. Gonzalez GM. In vitro activities of isavuconazole against opportunistic filamentous and dimorphic fungi. Med Mycol. 2009;47(1):71–6.

    Article  CAS  PubMed  Google Scholar 

  22. Lackner M, de Hoog GS, Verweij PE, et al. Species-specific antifungal susceptibility patterns of Scedosporium and Pseudallescheria species. Antimicrob Agents Chemother. 2012;56(5):2635–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Chowdhary A, Kathuria S, Randhawa HS, Gaur SN, Klaassen CH, Meis JF. Isolation of multiple-triazole-resistant Aspergillus fumigatus strains carrying the TR/L98H mutations in the cyp51A gene in India. J Antimicrob Chemother. 2012;67(2):362–6.

    Article  CAS  PubMed  Google Scholar 

  24. Sanglard D, Coste AT. Activity of isavuconazole and other azoles against Candida clinical isolates and yeast model systems with known azole resistance mechanisms. Antimicrob Agents Chemother. 2015;60(1):229–38.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Whaley SG, Berkow EL, Rybak JM, Nishimoto AT, Barker KS, Rogers PD. Azole antifungal resistance in Candida albicans and emerging non-albicans Candida species. Front Microbiol. 2016;7:2173.

    PubMed  Google Scholar 

  26. Astvad KM, Hare RK, Arendrup MC. Evaluation of the in vitro activity of isavuconazole and comparator voriconazole against 2635 contemporary clinical Candida and Aspergillus isolates. Clin Microbiol Infect. 2017;

  27. Howard SJ, Lass-Flörl C, Cuenca-Estrella M, Gomez-Lopez A, Arendrup MC. Determination of isavuconazole susceptibility of Aspergillus and Candida species by the EUCAST method. Antimicrob Agents Chemother. 2013;57(11):5426–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Schmitt-Hoffmann A, Desai A, Kowalski D, Pearlman H, Yamazaki T, Townsend R. Isavuconazole absorption following oral administration in healthy subjects is comparable to intravenous dosing, and is not affected by food, or drugs that alter stomach pH. Int J Clin Pharmacol Ther. 2016;54(8):572–80.

    Article  PubMed  Google Scholar 

  29. Schmitt-Hoffmann A, Roos B, Maares J, et al. Multiple-dose pharmacokinetics and safety of the new antifungal triazole BAL4815 after intravenous infusion and oral administration of its prodrug, BAL8557, in healthy volunteers. Antimicrob Agents Chemother. 2006;50(1):286–93.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. • Desai A, Kovanda L, Kowalski D, Lu Q, Townsend R, Bonate PL. Population pharmacokinetics of Isavuconazole from phase 1 and phase 3 (SECURE) trials in adults and target attainment in patients with invasive infections due to aspergillus and other filamentous fungi. Antimicrob Agents Chemother. 2016;60(9):5483–91. A population-based summary of isavuconazole pharmacokinetics. Demonstrates isavuconazole dosing principles and assists the read with dosing justification and discusses MIC breakpoint values

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Majithiya J, Sharp A, Parmar A, Denning DW, Warn PA. Efficacy of isavuconazole, voriconazole and fluconazole in temporarily neutropenic murine models of disseminated Candida tropicalis and Candida krusei. J Antimicrob Chemother. 2009;63(1):161–6.

    Article  CAS  PubMed  Google Scholar 

  32. Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62(4):e1–50.

    Article  PubMed  Google Scholar 

  33. Patterson TF, Thompson GR 3rd, Denning DW, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;63(4):e1–e60.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Stott KE, Hope WW. Therapeutic drug monitoring for invasive mould infections and disease: pharmacokinetic and pharmacodynamic considerations. J Antimicrob Chemother. 2017;72(suppl_1):i12–8.

    Article  PubMed  Google Scholar 

  35. Schmitt-Hoffmann A, Roos B, Spickermann J, et al. Effect of mild and moderate liver disease on the pharmacokinetics of isavuconazole after intravenous and oral administration of a single dose of the prodrug BAL8557. Antimicrob Agents Chemother. 2009;53(11):4885–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Desai A, Schmitt-Hoffmann AH, Mujais S, Townsend R. Population pharmacokinetics of Isavuconazole in subjects with mild or moderate hepatic impairment. Antimicrob Agents Chemother. 2016;60(5):3025–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. •• Maertens JA, Raad II, Marr KA, et al. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. Lancet. 2016;387(10020):760–9. Primary trial comparing isavuconazole to voriconazole. Reports safety and efficacy endpoints for the treatment of invasive mould disease. This study demonstrates that isavuconazole is safe equally effective as other triazole antifungal agents.

    Article  CAS  PubMed  Google Scholar 

  38. Noxafil ® (posaconazole) [package insert]. Whitehouse Station, NJ: Merck & Co., Inc; 2006.

  39. Diflucan ® (fluconazole) [package insert]. New York, NY: Pfizer; 1988.

  40. Cresemba® (isavuconazonium sulfate) [package insert]. Northbrook, IL: Astellas Pharma US, Inc; 2015.

  41. Vfend ® (voriconazole) [package insert]. New York, NY: Pfizer; 2002. In.

  42. Sporanox® (itraconazole) [package insert]. Raritan, NJ: Janssen Pharmaceuticals, Inc.; 2003.

  43. Yamazaki T, Desai A, Han D, et al. Pharmacokinetic interaction between isavuconazole and a fixed-dose combination of lopinavir 400 mg/ritonavir 100 mg in healthy subjects. Clin Pharmacol Drug Dev. 2017;6(1):93–101.

    Article  CAS  PubMed  Google Scholar 

  44. Yamazaki T, Desai A, Goldwater R, et al. Pharmacokinetic effects of isavuconazole coadministration with the cytochrome P450 enzyme substrates bupropion, repaglinide, caffeine, dextromethorphan, and methadone in healthy subjects. Clin Pharmacol Drug Dev. 2017;6(1):54–65.

    Article  CAS  PubMed  Google Scholar 

  45. Yamazaki T, Desai A, Goldwater R, et al. Pharmacokinetic interactions between isavuconazole and the drug transporter substrates atorvastatin, digoxin, metformin, and methotrexate in healthy subjects. Clin Pharmacol Drug Dev. 2017;6(1):66–75.

    Article  CAS  PubMed  Google Scholar 

  46. Desai A, Yamazaki T, Dietz AJ, et al. Pharmacokinetic and pharmacodynamic evaluation of the drug-drug interaction between isavuconazole and warfarin in healthy subjects. Clin Pharmacol Drug Dev. 2017;6(1):86–92.

    Article  CAS  PubMed  Google Scholar 

  47. Kim T, Jancel T, Kumar P, Freeman AF. Drug-drug interaction between isavuconazole and tacrolimus: a case report indicating the need for tacrolimus drug-level monitoring. J Clin Pharm Ther. 2015;

  48. Groll AH, Desai A, Han D, et al. Pharmacokinetic assessment of drug-drug interactions of isavuconazole with the immunosuppressants cyclosporine, mycophenolic acid, prednisolone, sirolimus, and tacrolimus in healthy adults. Clin Pharmacol Drug Dev. 2017;6(1):76–85.

    Article  CAS  PubMed  Google Scholar 

  49. Lewis RE. Current concepts in antifungal pharmacology. Mayo Clin Proc. 2011;86(8):805–17.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Kyriakidis I, Tragiannidis A, Munchen S, Groll AH. Clinical hepatotoxicity associated with antifungal agents. Expert Opin Drug Saf. 2017;16(2):149–65.

    CAS  PubMed  Google Scholar 

  51. Keirns J, Desai A, Kowalski D, et al. QT interval shortening with isavuconazole: in vitro and in vivo effects on cardiac repolarization. Clin Pharmacol Ther. 2017;101(6):782–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Seyedmousavi S, Bruggemann RJ, Meis JF, Melchers WJ, Verweij PE, Mouton JW. Pharmacodynamics of isavuconazole in an Aspergillus fumigatus mouse infection model. Antimicrob Agents Chemother. 2015;59(5):2855–66.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Seyedmousavi S, Brüggemann RJM, Meis JF, Melchers WJG, Verweij PE, Mouton JW. Pharmacodynamics of isavuconazole in an Aspergillus fumigatus mouse infection model. Antimicrob Agents Chemother. 2015;59(5):2855–66.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Lepak AJ, Marchillo K, VanHecker J, Andes DR. Posaconazole pharmacodynamic target determination against wild-type and Cyp51 mutant isolates of aspergillus fumigatus in an in vivo model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother. 2013;57(1):579–85.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Forastiero A, Bernal-Martinez L, Mellado E, Cendejas E, Gomez-Lopez A. In vivo efficacy of voriconazole and posaconazole therapy in a novel invertebrate model of Aspergillus fumigatus infection. Int J Antimicrob Agents. 2015;46(5):511–7.

    Article  CAS  PubMed  Google Scholar 

  56. Kovanda LL, Petraitiene R, Petraitis V, et al. Pharmacodynamics of isavuconazole in experimental invasive pulmonary aspergillosis: implications for clinical breakpoints. J Antimicrob Chemother. 2016;71(7):1885–91.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Ahmed Y, Delaney S, Markarian A. Successful isavuconazole therapy in a patient with acute invasive fungal rhinosinusitis and acquired immune deficiency syndrome. Am J Otolaryngol. 2016;37(2):152–5.

    Article  PubMed  Google Scholar 

  58. Martin MS, Smith AA, Lobo M, Paramesh AS. Successful treatment of recurrent pulmonary mucormycosis in a renal transplant patient: a case report and literature review. Case Rep Transplant. 2017;2017:1925070.

    PubMed  PubMed Central  Google Scholar 

  59. Ervens J, Ghannoum M, Graf B, Schwartz S. Successful isavuconazole salvage therapy in a patient with invasive mucormycosis. Infection. 2014;42(2):429–32.

    Article  CAS  PubMed  Google Scholar 

  60. Peixoto D, Gagne LS, Hammond SP, et al. Isavuconazole treatment of a patient with disseminated mucormycosis. J Clin Microbiol. 2014;52(3):1016–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. News Release. Astellas provides update on phase 3 study evaluating isavuconazole in patients with candidemia and other invasive Candida infections. Available from: http://newsroom.astellas.us/2015-07-30-Astellas-Provides-Update-on-Phase-3-Study-Evaluating-Isavuconazole-in-Patients-with-Candidemia-and-Other-Invasive-Candida-Infections. July 30 2015. Accessed May 20 2017.

  62. Andes DR, Safdar N, Baddley JW, et al. Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials. Clin Infect Dis. 2012;54(8):1110–22.

    Article  CAS  PubMed  Google Scholar 

  63. Viljoen J, Azie N, Schmitt-Hoffmann AH, Ghannoum M. A phase 2, randomized, double-blind, multicenter trial to evaluate the safety and efficacy of three dosing regimens of isavuconazole compared with fluconazole in patients with uncomplicated esophageal candidiasis. Antimicrob Agents Chemother. 2015;59(3):1671–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. Thompson GR, Rendon A, Ribeiro Dos Santos R, et al. Isavuconazole treatment of cryptococcosis and dimorphic mycoses. Clin Infect Dis. 2016;63(3):356–62.

    Article  PubMed  PubMed Central  Google Scholar 

  65. Wiederhold NP, Kovanda L, Najvar LK, et al. Isavuconazole is effective for the treatment of experimental cryptococcal meningitis. Antimicrob Agents Chemother. 2016;60(9):5600–3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 2007;356(4):348–59.

    Article  CAS  PubMed  Google Scholar 

  67. Cornely OA, Bohme A, Schmitt-Hoffmann A, Ullmann AJ. Safety and pharmacokinetics of isavuconazole as antifungal prophylaxis in acute myeloid leukemia patients with neutropenia: results of a phase 2, dose escalation study. Antimicrob Agents Chemother. 2015;59(4):2078–85.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. • Horn D, Goff D, Khandelwal N, et al. Hospital resource use of patients receiving isavuconazole vs voriconazole for invasive mold infections in the phase III SECURE trial. J Med Econ. 2016;19(7):728–34. This reference critically analyzes the cost associated with new antifungal therapy. The comprehensive analysis of hospital drug costs are important when considering initial antifungal therapy options

    Article  PubMed  Google Scholar 

  69. Harrington R, Lee E, Yang H, et al. Cost-effectiveness analysis of isavuconazole vs. voriconazole as first-line treatment for invasive aspergillosis. Adv Ther. 2017;34(1):207–20.

    Article  PubMed  Google Scholar 

  70. Petrikkos G, Skiada A, Lortholary O, Roilides E, Walsh TJ, Kontoyiannis DP. Epidemiology and clinical manifestations of mucormycosis. Clin Infect Dis. 2012;54(Suppl 1):S23–34.

    Article  PubMed  Google Scholar 

  71. Bagshaw E, Kuessner D, Posthumus J, et al. The cost of treating mucormycosis with isavuconazole compared with standard therapy in the UK. Future Microbiol. 2017;12:515–25.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Wisconsin Health, 600 Highland Ave MC-1530, Madison, WI, 53792, USA

    Erin K. McCreary PharmD, BCPS & Lucas T Schulz PharmD, BCPS (AQ-ID)

  2. University of Wisconsin School of Medicine and Public Health, 1685 Highland Ave, Madison, WI, 53705 2281, USA

    Alexander J. Lepak MD

Authors
  1. Erin K. McCreary PharmD, BCPS
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lucas T Schulz PharmD, BCPS (AQ-ID)
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Alexander J. Lepak MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lucas T Schulz PharmD, BCPS (AQ-ID).

Ethics declarations

Conflict of interest

Erin K. McCreary declares that she has no conflict of interest. Lucas T Schulz declares that he has no conflict of interest. Alexander J. Lepak declares that he has no conflict of interest.

Human and animal rights and informed consent

With regard to the authors’ research cited in this paper, all procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. In addition, all applicable international, national, and/or institutional guidelines for the care and use of animals were followed.

Additional information

This article is part of the Topical Collection on Fungal Infections

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

McCreary, E.K., Schulz, L.T. & Lepak, A.J. Isavuconazole: Has It Saved Us? A Pharmacotherapy Review and Update on Clinical Experience. Curr Treat Options Infect Dis 9, 356–370 (2017). https://doi.org/10.1007/s40506-017-0133-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40506-017-0133-9

Keywords

Search

Navigation